lorviqua
pfizer europe ma eeig - lorlatinib - karcinom, ne-malih stanica pluća - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
nebilet plus 25 5 mg/1 tableta+ 25 mg/1 tableta film tableta
berlin chemie / menarini bh d.o.o. sarajevo - hidrohlorotiazid, Небиволол - film tableta - 5 mg/1 tableta+ 25 mg/1 tableta - 1 film tableta sadrži: 5 mg nebivolol (u obliku nebivololhidrohlorida) i 25 mg hidrohlorotiazid
nebilet plus 12,5 5 mg/1 tableta+ 12.5 mg/1 tableta film tableta
berlin chemie / menarini bh d.o.o. sarajevo - hidrohlorotiazid, Небиволол - film tableta - 5 mg/1 tableta+ 12.5 mg/1 tableta - 1 film tableta sadrži: 5 mg nebivolol (u obliku nebivololhidrohlorida) i 12,5 mg hidrohlorotiazid
mezym 20000 160 mg/1 tableta 222,22 mg/1 tableta želučanootporna tableta
berlin chemie / menarini bh d.o.o. sarajevo - pankreatin - želučanootporna tableta - 160 mg/1 tableta 222,22 mg/1 tableta - 1 želučanootporna tableta sadrži 160 mg 222,22 mg pancreas praška sa minimalnom aktivnosti: lipaza 20 000 ph.eur. jedinica; amilaza 12 000 ph.eur. jedinica; proteaza 900 ph.eur. jedinica
dovprela (previously pretomanid fgk)
mylan ire healthcare limited - pretomanid - tuberkuloza, višestruko otporna - antimikobakterija - dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (xdr), or treatment-intolerant or nonresponsive multidrug-resistant (mdr) tuberculosis (tb). treba uzeti u obzir formalne preporuke za odgovarajuće korištenje antibakterijskih posrednika.
tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - karcinom, ne-malih stanica pluća - antineoplastična sredstva - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
nebilet plus 25 5 mg/1 tableta+ 25 mg/1 tableta film tableta
berlin chemie / menarini bh d.o.o. sarajevo - hidrohlorotiazid, Небиволол - film tableta - 5 mg/1 tableta+ 25 mg/1 tableta - 1 film tableta sadrži: 5 mg nebivolola (u obliku nebivololhidrohlorida) i 25 mg hidrohlorotiazida
nebilet plus 12,5 5 mg/1 tableta+ 12.5 mg/1 tableta film tableta
berlin chemie / menarini bh d.o.o. sarajevo - hidrohlorotiazid, Небиволол - film tableta - 5 mg/1 tableta+ 12.5 mg/1 tableta - 1 film tableta sadrži: 5 mg nebivolola (u obliku nebivololhidrohlorida) i 12,5 mg hidrohlorotiazida
lorviqua 25 mg/1 tableta filmom obložena tableta
pfizer bh d.o.o. sarajevo - lorlatinib - filmom obložena tableta - 25 mg/1 tableta - 1 filmom obložena tableta sadrži 25 mg lorlatiniba
lorviqua 100 mg/1 tableta filmom obložena tableta
pfizer bh d.o.o. sarajevo - lorlatinib - filmom obložena tableta - 100 mg/1 tableta - 1 filmom obložena tableta sadrži 100 mg lorlatiniba